Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Dupuytren's Disease: later-stage trial registry

1 of 5 indexed Dupuytren's Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Dupuytren's Disease: 5 US clinical trials tracked, 1 recruiting.

Dupuytren's Disease is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Endo Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition dupuytrens-disease

OPEN 1 | RECR 20% | LATE 3 | EARLY 1 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Dupuytren's Disease (this)20%
Open-enrollment share among volume-matched conditions near Dupuytren's Disease

Dupuytren's Disease lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dupuytren's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dupuytren's Disease is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Dupuytren's Disease research.

    Endo Pharmaceuticals accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Dupuytren's Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. Dupuytren's Disease research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 32Phase 41

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Dupuytren's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Collagenase clostridium histolyticum Biological
1 trials
Xiaflex + Hand-Based Custom Orthosis Combination
1 trials
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] Drug
1 trials
XIAFLEX Biological
1 trials
collagenase clostridium histolyticum Biological
1 trials
Evaluation of Dupuytren's Disease Treatment Other
1 trials
Placebo Biological
1 trials

US sites by state

Facility locations filed on Dupuytren's Disease trials. A trial with sites in several states counts in each.

New York 3 trials
Pennsylvania 1 trials
Oklahoma 1 trials
North Carolina 1 trials
Minnesota 1 trials
Indiana 1 trials
Florida 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dupuytren's Disease page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dupuytren's Disease condition card totals 5 registered trials; most-linked intervention Collagenase clostridium histolyticum; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.